{"url_path":"/sec/cadl/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-222904-index.html","accession_number":"0001193125-26-222904","cik":"0001841387","ticker":"CADL","issuer_name":"Candel Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-222904-index.html","primary_entity_key":"0001841387","primary_entity_name":"Candel Therapeutics, Inc."},"word_count":378,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nThe following table describes contracts, instructions or written plans for the sale or purchase of our securities adopted by our directors and certain officers during the three months ended March 31, 2026, each of which is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c), referred to as Rule 10b5-1 trading plans.\n\n \n\nName\n\nAction Taken\n\nNature of Trading Arrangement\n\nDuration of Trading Arrangement\n\nAggregate Number of Securities\n\nPaul Peter Tak, M.D., Ph.D., FMedSci (Chief Executive Officer, President and Director)\n\nAdoption (March 13, 2026)\n\nTrading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)\n\nEarlier of (i) June 30, 2027 and (ii) the completed sale of the maximum aggregate number of securities under the plan\n\nUp to 880,245 shares\n\nCharles Schoch (Chief Financial Officer, Treasurer and Secretary)\n\nAdoption (March 13, 2026)\n\nTrading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)\n\nEarlier of (i) June 30, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan\n\nUp to 38,038 shares\n\nFrancesca Barone, M.D., Ph.D. (Chief Scientific Officer)\n\nAdoption (March 16, 2026)\n\nTrading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)\n\nEarlier of (i) June 30, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan\n\nUp to 93,789 shares\n\nW. Garrett Nichols, M.D., M.S. (Chief Medical Officer)\n\nAdoption (March 16, 2026)\n\nTrading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)\n\nEarlier of (i) November 1, 2027 and (ii) the completed sale of the maximum aggregate number of securities under the plan\n\nUp to 52,493 shares\n\nSeshu Tyagarajan, Ph.D., RAC (Chief Technical and Development Director)\n\nAdoption (March 16, 2026)\n\nTrading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c)\n\nEarlier of (i) March 31, 2028 and (ii) the completed sale of the maximum aggregate number of securities under the plan\n\nUp to 128,564 shares\n\n \n\nNo other directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the three months ended March 31, 2026.\n\n91"}